Global and USA Biosimilar Market: Latest updates from Hospira, Sandoz, Merck, Teva, Boehringer Ingelheim

The global biosimilar and biobetter market is presenting lucrative opportunities to drug developers and manufacturers. Companies are no longer just looking at regional market, but must align global strategy for commercialization. This is easier said than done, especially with significant regulations and licensing differences.

The 2nd annual Biosmilars & Biobetters USA conference, taking place in Iselin, New Jersey, USA, on the 16th and 17th of November 2015, will bring in selected regional experts including regulators to answer the key questions:

• The first biosimilar approved by the FDA. Looking at this case in detail, how did it progress and how will it develop
  Speaker: John Pakulski, Head US Biopharmaceutical Regulatory Affairs, Sandoz Inc.
• From approval to clinical use – what are the differences between the US and Europe?
  Speaker: Steinar Madsen, Medical Director, Norwegian Medicine Agency
• Clinical and regulatory strategies encompassing the needs of East and West: What are the key features of a truly global development programme?
  Speaker: Gerry McGettigan, CEO, Kinesys Consulting Ltd and COO, amp Biosimilars AG (Germany)
• Where are we now and how will we develop? Lessons learned from the first European & US biosimilars
  Speaker: Carsten Brockmeyer, CEO, Formycon AG, (Germany)
• Understanding the blurred lines between traditional innovators and generics
  Speaker: Andrea Laslop, Austrian Agency for Health & Food Safety

Biosimilars & Biobetters USA official website: www.biosimilars-usa.com/drugtargetreveiew

Event speakers 2015 also include top decision makers from Merck Serono SA, Harvest Moon Pharmaceuticals USA, IMS Health, Dr. Reddy’s Laboratories, Selecta Biosciences, MedImmune and many more.

Attendees 2015 include confirmed representatives from: Boehringer Ingelheim, Hospira, Janssen, Merck, Samsung Bioepis, Sandoz, Teva Pharmaceuticals, BioOutsource, Fairleigh Dickinson University, FFF Enterprise, Publicis Healthcare Communications Group, Maxcess Managed Markets, Abzena, Wyatt Health Management, Vince & Associates Clinical Research and many more.

Event programme 2015 includes 2 Opening Addresses, 1 Spotlight Presentation, 15 Hand-Picked Case Study Based Presentations, 1 Panel Debate and 2 Exclusive Interactive Workshops. Register today to network with leading biosimilar experts and hear the latest on the evolving regulatory biosimilar landscape, gain understanding on the barriers being faced for market access and commercialization of products through case-study led presentations plus much more.

The event programme also includes 2 interactive half-day post-conference workshops: “A Regulatory Perspective on Biosimilars” (Hosted by Ravi S. Harapanhalli, Ph.D. Principal, FDAPharma Consulting) and “Development, Regulatory & Commercial Needs for Global Biosimilars “(Hosted by Gerry McGettigan, CEO & Regulatory Expert, and Graeme Deuchar, Product Development Expert, Kinesys Consulting Ltd, and Liz Yamashita, VP, Regulatory & Clinical Affairs, Oncobiologics).

Places are strictly limited to ensure an interactive dialogue and optimal learning outcome.

Please visit www.biosimilars-usa.com/drugtargetreveiew to download a complimentary copy of the event brochure with agenda breakdown, information on workshops and registration form.

Due to high demand, availability to attend Biosimilars & Biobetters USA 2015 is now limited. To secure your attendance book online today at www.biosimilars-usa.com/drugtargetreveiew or contact Fateja Begum on tel: +44 (0) 207 827 6184 / Email: [email protected]

Biosimilars & Biobetters USA 2015 is proudly sponsored by Schwegman Lundberg & Woessner. Supported by Drug Target Review.

Early bird places are strictly limited. To take advantage of this, please register today at www.biosimilars-usa.com/drugtargetreveiew